Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA

15-Jun-2010 - USA

Genzyme Corporation announced that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

The FDA's Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Under Fast Track designation, alemtuzumab for MS is eligible for Priority Review and the FDA may consider for review portions of the marketing application before the submission of a New Drug Application (NDA) is completed.

“We are extremely pleased that our alemtuzumab development program has been assigned Fast Track status, and look forward to working closely with the FDA to expedite the program’s review process,” said Henri Termeer, Genzyme’s chairman and chief executive officer. “Alemtuzumab is a potentially transformative therapy for the treatment of multiple sclerosis, and an important part of our future.”

Alemtuzumab for the treatment of MS is currently being evaluated in two pivotal multi-center, multi-national trials, known as CARE-MS SM (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis). The company’s CARE-MS I Phase 3 trial is a randomized study comparing alemtuzumab to the approved therapy Rebif (high-dose interferon beta-1a) in early, relapsing-remitting multiple sclerosis (RRMS) patients who have received no prior therapy. The second Phase 3 trial, CARE-MS II, is comparing alemtuzumab to Rebif in RRMS patients who had active disease while on other MS therapies.

Both trials are fully enrolled and data are expected to be available in 2011.

https://www.bionity.com/en/news/118945/genzymes-alemtuzumab-for-treatment-of-multiple-sclerosis-granted-fast-track-status-by-fda.html